Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine A plus standard treatment versus standard treatment in hospitalized COVID-19 patients
2020-001262-11Phase 4Completed
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Start
- Apr 2020
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of cyclosporine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz. Primary endpoint: Proportion of patients in a non-serious category at 12 days of treatment. Started Apr 2020; status: completed.
02
Drugs
cyclosporine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001262-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001262-11.